Nivolumab + ipilimumab (NIVO + IPI) adjuvant versus placebo dans le carcinome rénal localisé à haut risque de récidive après néphrectomie : résultats de l'étude de phase 3 randomisée Checkmate...

Authors :: Barthélémy, P.
Motzer, R.
Russo, P.
Grünwald, V.
Tomita, Y.
Zurawski, B.
Parikh, O.
Buti, S.
Goh, J.
Ye, D.
Lingua, A.
Lattouf, J.
Escudier, B.
George, S.
Shuch, B.
Simsek, B.
Spiridigliozzi, J.
Chudnovsky, A.
Bex, A.
Source :: Proges en Urologie; 2022 Supplement, Vol. 32 Issue 3, pS88-S88, 1p
Publication Year :: 2022
Abstract: <i>Copyright of Proges en Urologie is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)

Full Text Access

Tools